57 years of value creation in the pharma industry: A story worth telling
The Tsetis Pharmaceutical Group of Companies (OFET), comprises two complimentary, dynamic pharma companies, Uni-pharma SA and InterMed SA, as well as a Cyprus-based commercial company, Pharmabelle, and the newly established Uniherbo, specializing in medicinal plant extraction.
Kleon Tsetis, a restless pharmacist and researcher, with a vision to strengthen the position of Greek manufacturing in the pharmaceutical industry, established Uni-Pharma in 1963 with the mission to improve the quality of life of our fellow men by facilitating access to treatment with innovative, high-quality, GMP and cost-efficient pharmaceutical products. Since its establishment, UNI-PHARMA has been active in research, development, manufacturing and marketing pharmaceuticals of the highest quality, covering all major therapeutic categories, with innovative highlight brands such as APOTEL® and SALOSPIR®, as well as technological challenges such as T4®, and the new TREBON GRIPPE day & night.
Since its foundation, Uni-Pharma has grown from a small privately-held company into a large and dynamic organization, which currently holds the leading position in unit sales among Greek-owned companies in the domestic market. In order to sustain this growth, Uni-Pharma actively explores collaboration potential with commercial partners and academic Institutions, on a global scale, while tirelessly investing in technology and manufacturing excellence. Through undaunted efforts, Uni-Pharma’s reach today extends to five continents and 47 countries (together, Uni-pharma and InterMed export to more than 66 countries worldwide), leveraging on growth opportunities around the globe. UNI-PHARMA exports high-technology and innovative products under its own brands, creating value and contributing to the great national effort of re-shaping the character and dynamic of Greece’s economy.
Accountability during the Pandemic – The generous donation by Unikinon
Uni-pharma stands out not only for its financial results, but also for its Corporate Responsibility policy, which was once again highlighted in the context of the COVID-19 pandemic. Specifically, the company’s management, with a sense of historical and social responsibility, donated to the Greek state 24 million free doses of Unikinon (chloroquine) and an additional 60,000 doses of the same drug to Cyprus government.
It is worth noting that the entire process of purchasing raw material, production of the drug and implementation of the donation, was carried out on the initiative of the President and CEO of OFET, Mrs. Ioulia Tseti.
Research, Patents, Investments
With regard to research, the firm has expanded far beyond the realm of pharmaceutical technology and innovation, as it has already filed/holds 62 national (50 related to Uni-Pharma and 12 to InterΜed products) and 24 international (20 related to Uni-Pharma and 4 to InterΜed products) patent applications/patents, some of them granted in more than 60 countries worldwide. Only in the past three years, the firm has filed 22 new national and international patent applications in the fields of pharmaceutical active substance development and novel pharmaceutical and nutritional compositions. In addition, the Group is currently preparing 9 research programs, of which 7 relate directly or indirectly to the utilization of the country’s biodiversity. The programs are implemented in collaboration with Academic and Research Institutions.
OFET has invested more than 80 million euros in recent years, while the investment plan for the years 2019-2021 exceeds 15 million euros with the completion of the radical renovation of Uni-pharma’s first and historic factory, on the Athens-Lamia National Road.
At the same time, a state-of-the-art privately-owned Logistics Center is being created to serve the needs of the Group’s second industry, InterMed.
Excellence, Awards, Recognitions
Throughout the years, Uni-Pharma has received Excellence Awards by numerous Institutions, both nationally and internationally, either for its products or innovative business practices and procedures.
In the family of Sustainability & UN Global Compact
Uni-pharma is a proud member of the United Nations Global Compact by complying with the 17 goals, such as, sustainable development, environmental protection, abolition of child labor and eradicating corruption.
Tsetis Pharmaceutical Group of Companies also belongs – as of December 2020, to the leading group of “The Most Sustainable Companies in Greece 2020”, i.e. companies with the greatest sustainable growth. These 25 Greek model companies are highlighted in the Business Charter of Sustainable Development in our country. They operate as examples of good business and ethical practice. This is a technical evaluation, carried out by the executives of the Quality Net Foundation Network.
A robust CSR Strategy
The firm’s robust CSR Strategy entails significant actions and initiatives for the environment, access to health services, quality of life and well-being, cultivating a culture of voluntarism and solidarity.
Last but not least, the Kleon Tsetis foundation supports, among many other things, science and youth with a significant number of scholarships for the new generation of Greek scientists, in order to create favourable conditions for brilliant Greek minds to avoid the brain drain trend, which has emerged in recent years as a result of the country’s financial crisis.